Why the study?
Do sulfinpyrazone and ibuprofen have an optimal dose that inhibits platelet aggregation without interfering with prostaglandin-mediated coronary vasodilation in a canine model?
Do sulfinpyrazone and ibuprofen have an optimal dose that inhibits platelet aggregation without interfering with prostaglandin-mediated coronary vasodilation in a canine model?
Acute administration of sulfinpyrazone and ibuprofen in a canine model showed that doses inhibiting platelet function also inhibit beneficial coronary vasodilation, suggesting no optimal dose exists to separate these effects.
Answers are grounded in this paper and cite their sources.
No separable dose in canine model; leaves open whether selective antiplatelet effects are feasible clinically.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Goldstein et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: